-
平臺編號：bio-69141
-
國際編號：CRL-2343?
-
細(xì)胞信息： HCC2218
-
規(guī)格：Frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費用：
加載中…… - 訂購
-
注意事項：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
HCC2218
年限：TNM stage IIIA, grade 3
運輸方式：凍存運輸
生長狀態(tài)：懸浮生長
細(xì)胞形態(tài)：上皮樣
組織來源：duct
是否是腫瘤細(xì)胞：1
物種來源：人
ATCC Number：CRL-2343?
相關(guān)疾?。簩?dǎo)管癌
器官來源：乳房
數(shù)量：大量
規(guī)格：300 ul Designations: HCC2218
Depositors: ?AF Gazdar, AK Virmani
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension, The cells grow as floating aggregates of large cell clusters.
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: mammary gland; breast
Tissue: duct
Tumor Stage: TNM stage IIIA, grade 3
Disease: primary ductal carcinoma
Cellular Products:Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.
Applications:HCC2218 was derived from a female whose family members included several members with cancer; four lung cancer patients (two of them, non-smokers), two breast cancer patients (one of them also had lung cancer) and one colon cancer patient.
HCC2218 is a poorly differentiated cell line derived from the primary tumor of an invasive ductal carcinoma with metastases in 42/43 lymph nodes.
The cells are highly positive for expression of Her2/neu, and are also positive for expression of p53.
HCC2218 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 [EGP2] and for cytokeratin 19.
The cells are negative for expression of estrogen receptor (ER -).
Oncogene:her2/neu +, p53 +
Cytogenetic Analysis:polyploid
Age: 38 years adult
Gender: female
Ethnicity: Caucasian, White
Comments:The HCC2218 cell line was initiated on April 10, 1996, and took 6 months to establish.
HCC2218 was derived from a female whose family members included several members with cancer; four lung cancer patients (two of them, non-smokers), two breast cancer patients (one of them also had lung cancer) and one colon cancer patient.
HCC2218 is a poorly differentiated cell line derived from the primary tumor of an invasive ductal carcinoma with metastases in 42/43 lymph nodes.
The cells are highly positive for expression of Her2/neu, and are also positive for expression of p53.
HCC2218 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 [EGP2] and for cytokeratin 19.
The cells are negative for expression of estrogen receptor (ER -).
An EBV transformed lymphoblastoid cell line [HCC2218 BL] from the same patient is available as ATCC CRL-2363 .
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
normal (or near-normal) cell line established from the same patient:ATCC CRL-2363
References: 38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771
運輸方式：凍存運輸
生長狀態(tài)：懸浮生長
細(xì)胞形態(tài)：上皮樣
組織來源：duct
是否是腫瘤細(xì)胞：1
物種來源：人
ATCC Number：CRL-2343?
相關(guān)疾?。簩?dǎo)管癌
器官來源：乳房
數(shù)量：大量
規(guī)格：300 ul Designations: HCC2218
Depositors: ?AF Gazdar, AK Virmani
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension, The cells grow as floating aggregates of large cell clusters.
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: mammary gland; breast
Tissue: duct
Tumor Stage: TNM stage IIIA, grade 3
Disease: primary ductal carcinoma
Cellular Products:Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.
Applications:HCC2218 was derived from a female whose family members included several members with cancer; four lung cancer patients (two of them, non-smokers), two breast cancer patients (one of them also had lung cancer) and one colon cancer patient.
HCC2218 is a poorly differentiated cell line derived from the primary tumor of an invasive ductal carcinoma with metastases in 42/43 lymph nodes.
The cells are highly positive for expression of Her2/neu, and are also positive for expression of p53.
HCC2218 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 [EGP2] and for cytokeratin 19.
The cells are negative for expression of estrogen receptor (ER -).
Oncogene:her2/neu +, p53 +
Cytogenetic Analysis:polyploid
Age: 38 years adult
Gender: female
Ethnicity: Caucasian, White
Comments:The HCC2218 cell line was initiated on April 10, 1996, and took 6 months to establish.
HCC2218 was derived from a female whose family members included several members with cancer; four lung cancer patients (two of them, non-smokers), two breast cancer patients (one of them also had lung cancer) and one colon cancer patient.
HCC2218 is a poorly differentiated cell line derived from the primary tumor of an invasive ductal carcinoma with metastases in 42/43 lymph nodes.
The cells are highly positive for expression of Her2/neu, and are also positive for expression of p53.
HCC2218 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 [EGP2] and for cytokeratin 19.
The cells are negative for expression of estrogen receptor (ER -).
An EBV transformed lymphoblastoid cell line [HCC2218 BL] from the same patient is available as ATCC CRL-2363 .
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
normal (or near-normal) cell line established from the same patient:ATCC CRL-2363
References: 38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771
